Distinct antifibrogenic effects of erlotinib, sunitinib and sorafenib on rat pancreatic stellate cells

World Journal of Gastroenterology

Volumn 20, Issue 24, 2014, Pages 7914-7925

  Elsner, Anne ^a   Lange, Falko ^a   Fitzner, Brit ^a   Heuschkel, Martin ^a   Krause, Bernd Joachim ^a   Jaster, Robert ^a  

^a ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

Author keywords

Erlotinib; Fibrosis; Pancreatic stellate cell; Sorafenib; Sunitinib

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; BROXURIDINE; COLLAGEN TYPE 1; ERLOTINIB; FLUORODEOXYGLUCOSE F 18; GELATINASE A; GELATINASE B; INTERLEUKIN 6; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SORAFENIB; SUNITINIB; TRANSFORMING GROWTH FACTOR BETA1; ACTIN; CARBANILAMIDE DERIVATIVE; COLLAGEN TYPE I, ALPHA 1 CHAIN; INDOLE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE; MMP2 PROTEIN, RAT; NICOTINAMIDE; PROTEIN KINASE INHIBITOR; PYRROLE DERIVATIVE; QUINAZOLINE DERIVATIVE; SMOOTH MUSCLE ACTIN, RAT; TGFB1 PROTEIN, RAT;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CANCER INHIBITION; CELL DEATH; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYSTIC FIBROSIS; CYTOTOXICITY; DNA CONTENT; DNA SYNTHESIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROGENESIS; FLOW CYTOMETRY; GENE EXPRESSION; GLUCOSE TRANSPORT; IMMUNOFLUORESCENCE TEST; MALE; NONHUMAN; PANCREAS CANCER; PANCREATIC STELLATE CELL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR UPREGULATION; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CULTURE; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; LEWIS RAT; METABOLISM; PANCREAS; PATHOLOGY; PHENOTYPE; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TIME;

ACTINS; ANIMALS; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; COLLAGEN TYPE I; DOSE-RESPONSE RELATIONSHIP, DRUG; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION REGULATION; INDOLES; MALE; MATRIX METALLOPROTEINASE 2; NIACINAMIDE; PANCREAS; PANCREATIC STELLATE CELLS; PHENOTYPE; PHENYLUREA COMPOUNDS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; PYRROLES; QUINAZOLINES; RATS, INBRED LEW; RNA, MESSENGER; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84903171011     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i24.7914     Document Type: Article

References (51)

1. Erkan M, Adler G, Apte MV, Bachem MG, Buchholz M, Detlefsen S, Esposito I, Friess H, Gress TM, Habisch HJ, Hwang RF, Jaster R, Kleeff J, Klöppel G, Kordes C, Logsdon CD, Masamune A, Michalski CW, Oh J, Phillips PA, Pinzani M, Reiser-Erkan C, Tsukamoto H, Wilson J. StellaTUM: current consensus and discussion on pancreatic stellate cell research. Gut 2012; 61: 172-178 [PMID: 22115911 DOI: 10.1136/gutjnl-2011-301220]
2. Bachem MG, Schneider E, Gross H, Weidenbach H, Schmid RM, Menke A, Siech M, Beger H, Grünert A, Adler G. Identification, culture, and characterization of pancreatic stellate cells in rats and humans. Gastroenterology 1998; 115: 421-432 [PMID: 9679048 DOI: 10.1016/S0016-5085(98)70209-4]
3. Apte MV, Haber PS, Applegate TL, Norton ID, McCaughan GW, Korsten MA, Pirola RC, Wilson JS. Periacinar stellate shaped cells in rat pancreas: identification, isolation, and culture. Gut 1998; 43: 128-133 [PMID: 9771417 DOI: 10.1136/ gut.43.1.128]
4. Haber PS, Keogh GW, Apte MV, Moran CS, Stewart NL, Crawford DH, Pirola RC, McCaughan GW, Ramm GA, Wilson JS. Activation of pancreatic stellate cells in human and experimental pancreatic fibrosis. Am J Pathol 1999; 155: 1087-1095 [PMID: 10514391 DOI: 10.1016/S00029440(10)65211-X]
5. Apte MV, Park S, Phillips PA, Santucci N, Goldstein D, Kumar RK, Ramm GA, Buchler M, Friess H, McCarroll JA, Keogh G, Merrett N, Pirola R, Wilson JS. Desmoplastic reaction in pancreatic cancer: role of pancreatic stellate cells. Pancreas 2004; 29: 179-187 [PMID: 15367883 DOI: 10.1097/00006676-2 00410000-00002]
6. Talukdar R, Saikia N, Singal DK, Tandon R. Chronic pancreatitis: evolving paradigms. Pancreatology 2006; 6: 440-449 [PMID: 16847381 DOI: 10.1159/000094561]
7. Vonlaufen A, Joshi S, Qu C, Phillips PA, Xu Z, Parker NR, Toi CS, Pirola RC, Wilson JS, Goldstein D, Apte MV. Pancreatic stellate cells: partners in crime with pancreatic cancer cells. Cancer Res 2008; 68: 2085-2093 [PMID: 18381413 DOI: 10.1158/0008-5472.CAN-07-2477]
8. Hwang RF, Moore T, Arumugam T, Ramachandran V, Amos KD, Rivera A, Ji B, Evans DB, Logsdon CD. Cancerassociated stromal fibroblasts promote pancreatic tumor progression. Cancer Res 2008; 68: 918-926 [PMID: 18245495 DOI: 10.1158/0008-5472.CAN-07-5714]
9. Müerköster S, Wegehenkel K, Arlt A, Witt M, Sipos B, Kruse ML, Sebens T, Klöppel G, Kalthoff H, Fölsch UR, Schäfer H. Tumor stroma interactions induce chemoresistance in pancreatic ductal carcinoma cells involving increased secretion and paracrine effects of nitric oxide and interleukin-1beta. Cancer Res 2004; 64: 1331-1337 [PMID: 14973050 DOI: 10.1158/0008-5472.CAN-03-1860]
10. Bachem MG, Schünemann M, Ramadani M, Siech M, Beger H, Buck A, Zhou S, Schmid-Kotsas A, Adler G. Pancreatic carcinoma cells induce fibrosis by stimulating proliferation and matrix synthesis of stellate cells. Gastroenterology 2005; 128: 907-921 [PMID: 15825074 DOI: 10.1053/ j.gastro.2004.12.036]
11. Qian LW, Mizumoto K, Maehara N, Ohuchida K, Inadome N, Saimura M, Nagai E, Matsumoto K, Nakamura T, Tanaka M. Co-cultivation of pancreatic cancer cells with orthotopic tumor-derived fibroblasts: fibroblasts stimulate tumor cell invasion via HGF secretion whereas cancer cells exert a minor regulative effect on fibroblasts HGF production. Cancer Lett 2003; 190: 105-112 [PMID: 12536083 DOI: 10.1016/ S0304-3835(02)00517-7]
12. Armstrong T, Packham G, Murphy LB, Bateman AC, Conti JA, Fine DR, Johnson CD, Benyon RC, Iredale JP. Type I collagen promotes the malignant phenotype of pancreatic ductal adenocarcinoma. Clin Cancer Res 2004; 10: 7427-7437 [PMID: 15534120 DOI: 10.1158/1078-0432.CCR-03-0825]
13. Schneiderhan W, Diaz F, Fundel M, Zhou S, Siech M, Hasel C, Möller P, Gschwend JE, Seufferlein T, Gress T, Adler G, Bachem MG. Pancreatic stellate cells are an important source of MMP-2 in human pancreatic cancer and accelerate tumor progression in a murine xenograft model and CAM assay. J Cell Sci 2007; 120: 512-519 [PMID: 17227797 DOI: 10.1242/jcs.03347]
14. Luttenberger T, Schmid-Kotsas A, Menke A, Siech M, Beger H, Adler G, Grünert A, Bachem MG. Platelet-derived growth factors stimulate proliferation and extracellular matrix synthesis of pancreatic stellate cells: implications in pathogenesis of pancreas fibrosis. Lab Invest 2000; 80: 47-55 [PMID: 10653002 DOI: 10.1038/labinvest.3780007]
15. Sparmann G, Glass A, Brock P, Jaster R, Koczan D, Thiesen HJ, Liebe S, Emmrich J. Inhibition of lymphocyte apoptosis by pancreatic stellate cells: impact of interleukin-15. Am J Physiol Gastrointest Liver Physiol 2005; 289: G842-G851 [PMID: 16002563 DOI: 10.1152/ajpgi.00483.2004]
16. Masamune A, Kikuta K, Satoh M, Sakai Y, Satoh A, Shimosegawa T. Ligands of peroxisome proliferator-activated receptor-gamma block activation of pancreatic stellate cells. J Biol Chem 2002; 277: 141-147 [PMID: 11606585 DOI: 10.1074/jbc.M107582200]
17. Jaster R, Lichte P, Fitzner B, Brock P, Glass A, Karopka T, Gierl L, Koczan D, Thiesen HJ, Sparmann G, Emmrich J, Liebe S. Peroxisome proliferator-activated receptor gamma overexpression inhibits pro-fibrogenic activities of immortalised rat pancreatic stellate cells. J Cell Mol Med 2005; 9: 670-682 [PMID: 16202214 DOI: 10.1111/j.1582-4934.2005.tb00497.x]
18. Baumert JT, Sparmann G, Emmrich J, Liebe S, Jaster R. Inhibitory effects of interferons on pancreatic stellate cell activation. World J Gastroenterol 2006; 12: 896-901 [PMID: 16521217 DOI: 10.3748/wjg.v12.i6.896]
19. Bülow R, Fitzner B, Sparmann G, Emmrich J, Liebe S, Jaster R. Antifibrogenic effects of histone deacetylase inhibitors on pancreatic stellate cells. Biochem Pharmacol 2007; 74: 1747-1757 [PMID: 17889833 DOI: 10.1016/j.bcp.2007.08.023]
20. Jaster R, Sparmann G, Emmrich J, Liebe S. Extracellular signal regulated kinases are key mediators of mitogenic signals in rat pancreatic stellate cells. Gut 2002; 51: 579-584 [PMID: 12235084 DOI: 10.1136/gut.51.4.579]
21. Masamune A, Kikuta K, Satoh M, Kume K, Shimosegawa T. Differential roles of signaling pathways for proliferation and migration of rat pancreatic stellate cells. Tohoku J Exp Med 2003; 199: 69-84 [PMID: 12705352 DOI: 10.1620/tjem.199.69]
22. McCarroll JA, Phillips PA, Kumar RK, Park S, Pirola RC, Wilson JS, Apte MV. Pancreatic stellate cell migration: role of the phosphatidylinositol 3-kinase(PI3-kinase) pathway. Biochem Pharmacol 2004; 67: 1215-1225 [PMID: 15006556 DOI: 10.1016/j.bcp.2003.11.013]
23. Ranieri G, Pantaleo M, Piccinno M, Roncetti M, Mutinati M, Marech I, Patruno R, Rizzo A, Sciorsci RL. Tyrosine kinase inhibitors (TKIs) in human and pet tumours with special reference to breast cancer: a comparative review. Crit Rev Oncol Hematol 2013; 88: 293-308 [PMID: 23768779 DOI: 10.1016/j.critrevonc.2013.05.009]
24. McCubrey JA, Milella M, Tafuri A, Martelli AM, Lunghi P, Bonati A, Cervello M, Lee JT, Steelman LS. Targeting the Raf/MEK/ERK pathway with small-molecule inhibitors. Curr Opin Investig Drugs 2008; 9: 614-630 [PMID: 18516761]
25. Wu P, Hu YZ. PI3K/Akt/mTOR pathway inhibitors in cancer: a perspective on clinical progress. Curr Med Chem 2010; 17: 4326-4341 [PMID: 20939811 DOI: 10.2174/0929867107933 61234]
26. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25: 1960-1966 [PMID: 17452677 DOI: 10.1200/JCO.2006.07.9525]
27. Zagouri F, Sergentanis TN, Chrysikos D, Zografos CG, Papadimitriou CA, Dimopoulos MA, Filipits M, Bartsch R. Molecularly targeted therapies in metastatic pancreatic cancer: a systematic review. Pancreas 2013; 42: 760-773 [PMID: 23774698 DOI: 10.1097/MPA.0b013e31827aedef]
28. Adnane L, Trail PA, Taylor I, Wilhelm SM. Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/ MEK/ERK pathway in tumor cells and tyrosine kinases VEG-FR/PDGFR in tumor vasculature. Methods Enzymol 2006; 407: 597-612 [PMID: 16757355 DOI: 10.1016/S0076-6879(05)07047-3]
29. Hasskarl J. Sorafenib. Recent Results Cancer Res 2010; 184: 61-70 [PMID: 20072831 DOI: 10.1007/978-3-642-01222-8_5]
30. Faivre S, Demetri G, Sargent W, Raymond E. Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov 2007; 6: 734-745 [PMID: 17690708 DOI: 10.1038/nrd2380]
31. Wood L. Sunitinib malate for the treatment of renal cell carcinoma. Expert Opin Pharmacother 2012; 13: 1323-1336 [PMID: 22607009 DOI: 10.1517/14656566.2012.689130]
32. Younus J, Verma S, Franek J, Coakley N, Sacroma Disease Site Group of Cancer Care Ontario's Program in EvidenceBased Care. Sunitinib malate for gastrointestinal stromal tumour in imatinib mesylate-resistant patients: recommendations and evidence. Curr Oncol 2010; 17: 4-10 [PMID: 20697509 DOI: 10.3747/co.v17i4.560]
33. Fitzner B, Lange A, Müller S, Jaster R. Cdkn1a is a key mediator of rat pancreatic stellate cell senescence. Pancreatology 2013; 13: 254-262 [PMID: 23719597 DOI: 10.1016/ j.pan.2013.03.009]
34. Rateitschak K, Karger A, Fitzner B, Lange F, Wolkenhauer O, Jaster R. Mathematical modelling of interferon-gamma signalling in pancreatic stellate cells reflects and predicts the dynamics of STAT1 pathway activity. Cell Signal 2010; 22: 97-105 [PMID: 19781632 DOI: 10.1016/j.cellsig.2009.09.019]
35. Aoki H, Ohnishi H, Hama K, Shinozaki S, Kita H, Yamamoto H, Osawa H, Sato K, Tamada K, Sugano K. Existence of autocrine loop between interleukin-6 and transforming growth factor-beta1 in activated rat pancreatic stellate cells. J Cell Biochem 2006; 99: 221-228 [PMID: 16598747 DOI: 10.1002/jcb.20906]
36. Mews P, Phillips P, Fahmy R, Korsten M, Pirola R, Wilson J, Apte M. Pancreatic stellate cells respond to inflammatory cytokines: potential role in chronic pancreatitis. Gut 2002; 50: 535-541 [PMID: 11889076 DOI: 10.1136/gut.50.4.535]
37. Moyer JD, Barbacci EG, Iwata KK, Arnold L, Boman B, Cunningham A, DiOrio C, Doty J, Morin MJ, Moyer MP, Neveu M, Pollack VA, Pustilnik LR, Reynolds MM, Sloan D, Theleman A, Miller P. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 1997; 57: 4838-4848 [PMID: 9354447]
38. Fenton MS, Marion KM, Salem AK, Hogen R, Naeim F, Hershman JM. Sunitinib inhibits MEK/ERK and SAPK/ JNK pathways and increases sodium/iodide symporter expression in papillary thyroid cancer. Thyroid 2010; 20: 965-974 [PMID: 20629553 DOI: 10.1089/thy.2010.0008]
39. Di Desidero T, Fioravanti A, Orlandi P, Canu B, Giannini R, Borrelli N, Man S, Xu P, Fontanini G, Basolo F, Kerbel RS, Francia G, Danesi R, Bocci G. Antiproliferative and proapoptotic activity of sunitinib on endothelial and anaplastic thyroid cancer cells via inhibition of Akt and ERK1/2 phosphorylation and by down-regulation of cyclin-D1. J Clin Endocrinol Metab 2013; 98: E1465-E1473 [PMID: 23969186 DOI: 10.1210/jc.2013-1364]
40. Saito Y, Tanaka Y, Aita Y, Ishii KA, Ikeda T, Isobe K, Kawakami Y, Shimano H, Hara H, Takekoshi K. Sunitinib induces apoptosis in pheochromocytoma tumor cells by inhibiting VEGFR2/Akt/mTOR/S6K1 pathways through modulation of Bcl-2 and BAD. Am J Physiol Endocrinol Metab 2012; 302: E615-E625 [PMID: 21878661 DOI: 10.1152/ajpendo.00035.2011]
41. Yeramian A, Sorolla A, Velasco A, Santacana M, Dolcet X, Valls J, Abal L, Moreno S, Egido R, Casanova JM, Puig S, Vilella R, Llombart-Cussac A, Matias-Guiu X, Martí RM. Inhibition of activated receptor tyrosine kinases by Sunitinib induces growth arrest and sensitizes melanoma cells to Bortezomib by blocking Akt pathway. Int J Cancer 2012; 130: 967-978 [PMID: 21445974 DOI: 10.1002/ijc.26096]
42. Yang F, Jove V, Xin H, Hedvat M, Van Meter TE, Yu H. Sunitinib induces apoptosis and growth arrest of medulloblastoma tumor cells by inhibiting STAT3 and AKT signaling pathways. Mol Cancer Res 2010; 8: 35-45 [PMID: 20053726 DOI: 10.1158/1541-7786.MCR-09-0220]
43. Ikezoe T, Yang Y, Nishioka C, Bandobashi K, Nakatani H, Taguchi T, Koeffler HP, Taguchi H. Effect of SU11248 on gastrointestinal stromal tumor-T1 cells: enhancement of growth inhibition via inhibition of 3-kinase/Akt/mammalian target of rapamycin signaling. Cancer Sci 2006; 97: 945-951 [PMID: 16916320 DOI: 10.1111/j.1349-7006.2006.00263.x]
44. Gedaly R, Angulo P, Hundley J, Daily MF, Chen C, Evers BM. PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation. J Surg Res 2012; 176: 542-548 [PMID: 22261591 DOI: 10.1016/j.jss.2011.10.045]
45. Gedaly R, Angulo P, Hundley J, Daily MF, Chen C, Koch A, Evers BM. PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways. Anticancer Res 2010; 30: 4951-4958 [PMID: 21187475]
46. Lu X, Tang X, Guo W, Ren T, Zhao H. Sorafenib induces growth inhibition and apoptosis of human chondrosarcoma cells by blocking the RAF/ERK/MEK pathway. J Surg Oncol 2010; 102: 821-826 [PMID: 20812347 DOI: 10.1002/jso.21661]
47. Kharaziha P, Rodriguez P, Li Q, Rundqvist H, Björklund AC, Augsten M, Ullén A, Egevad L, Wiklund P, Nilsson S, Kroemer G, Grander D, Panaretakis T. Targeting of distinct signaling cascades and cancer-associated fibroblasts define the efficacy of Sorafenib against prostate cancer cells. Cell Death Dis 2012; 3: e262 [PMID: 22278289 DOI: 10.1038/cddis.2012.1]
48. Carlo-Stella C, Locatelli SL, Giacomini A, Cleris L, Saba E, Righi M, Guidetti A, Gianni AM. Sorafenib inhibits lymphoma xenografts by targeting MAPK/ERK and AKT pathways in tumor and vascular cells. PLoS One 2013; 8: e61603 [PMID: 23620775 DOI: 10.1371/journal.pone.0061603]
49. Jaster R, Hilgendorf I, Fitzner B, Brock P, Sparmann G, Emmrich J, Liebe S. Regulation of pancreatic stellate cell function in vitro: biological and molecular effects of all-trans retinoic acid. Biochem Pharmacol 2003; 66: 633-641 [PMID: 12906928 DOI: 10.1016/S0006-2952(03)00390-3]
50. Villarroel MC, Pratz KW, Xu L, Wright JJ, Smith BD, Rudek MA. Plasma protein binding of sorafenib, a multi kinase inhibitor: in vitro and in cancer patients. Invest New Drugs 2012; 30: 2096-2102 [PMID: 22089297 DOI: 10.1007/s10637-011-9767-5]
51. Chen YL, Zhang X, Bai J, Gai L, Ye XL, Zhang L, Xu Q, Zhang YX, Xu L, Li HP, Ding X. Sorafenib ameliorates bleomycin-induced pulmonary fibrosis: potential roles in the inhibition of epithelial-mesenchymal transition and fibroblast activation. Cell Death Dis 2013; 4: e665 [PMID: 23764846 DOI: 10.1038/cddis.2013.154]